-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
modafinil	B-I
for	O
the	O
treatment	O
of	O
apathy	O
in	O
individuals	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
23	B-P
participants	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
probable	I-P
AD	I-P
according	I-P
to	I-P
National	I-P
Institute	I-P
of	I-P
Neurologic	I-P
and	I-P
Communicative	I-P
Disorder	I-P
and	I-P
Stroke	I-P
-	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
and	I-P
Related	I-P
Disorders	I-P
criteria	I-P
were	O
randomized	O
into	O
the	O
experimental	O
(	O
modafinil	B-I
200	O
mg	O
daily	O
)	O
or	O
control	O
(	O
placebo	B-C
)	O
groups	O
.	O

All	O
participants	O
were	O
also	O
receiving	O
stable	O
doses	O
of	O
a	O
cholinesterase	O
inhibitor	O
medication	O
.	O

Participants	O
completed	O
assessments	O
at	O
baseline	O
and	O
after	O
8	O
weeks	O
of	O
treatment	O
.	O

Outcome	O
measures	O
included	O
family	O
report	O
measures	O
of	O
apathy	B-O
,	O
ADL	B-O
performance	I-O
,	O
and	O
caregiver	B-O
burden	I-O
,	O
as	O
well	O
as	O
direct	O
assessment	O
of	O
ADL	B-O
performance	I-O
.	O

The	O
study	O
was	O
conducted	O
at	O
a	O
private	O
psychiatric	O
hospital	O
in	O
Rhode	O
Island	O
from	O
September	O
2005	O
until	O
September	O
2007	O
.	O

-DOCSTART-	O

Title	O
:	O
Heat	B-I
-	I-I
processed	I-I
ginseng	I-I
enhances	O
the	O
cognitive	O
function	O
in	O
patients	B-P
with	I-P
moderately	I-P
severe	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
Forty	B-P
patients	I-P
with	I-P
AD	I-P
were	O
randomized	O
into	O
one	O
of	O
three	O
different	O
dose	O
groups	O
or	O
the	O
control	O
group	O
as	O
follows	O
:	O
1	O
.	O
5	O
g	O
/	O
day	O
(	O
n	O
=	O
10	O
)	O
,	O
3	O
g	O
/	O
day	O
(	O
n	O
=	O
10	O
)	O
,	O
and	O
4	O
.	O
5	O
g	O
/	O
day	O
(	O
n	O
=	O
10	O
)	O
groups	O
,	O
or	O
control	O
(	O
n	O
=	O
10	O
)	O
.	O

The	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
(	I-O
ADAS	I-O
)	I-O
and	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
were	O
used	O
to	O
assess	O
cognitive	O
function	O
for	O
24	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Chinese	B-I
herbal	I-I
medicine	I-I
for	O
patients	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
disease	I-P
based	I-P
on	I-P
syndrome	I-P
differentiation	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
]	O
.	O

METHODS	O
:	O
Adopting	O
the	O
internationally	O
recognized	O
criteria	O
developed	O
by	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communicative	O
Diseases	O
and	O
Stroke	O
/	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
,	O
the	O
clinical	O
trial	O
was	O
conducted	O
on	O
131	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
from	I-P
5	I-P
communities	I-P
and	I-P
7	I-P
social	I-P
welfare	I-P
institutions	I-P
.	O

Participants	O
were	O
accepted	O
after	O
informed	O
consent	O
was	O
received	O
,	O
and	O
laboratory	O
tests	O
and	O
a	O
head	O
imaging	O
study	O
were	O
conducted	O
.	O

The	O
patients	O
were	O
randomly	O
divided	O
into	O
Chinese	B-I
medicine	I-I
group	O
(	O
CMG	O
)	O
(	O
66	O
cases	O
)	O
or	O
Western	B-I
medicine	I-I
group	O
(	O
WMG	O
)	O
(	O
65	O
cases	O
)	O
.	O

Patients	O
in	O
the	O
CMG	O
were	O
treated	O
monthly	O
with	O
Chinese	B-I
medicine	I-I
according	O
to	O
syndrome	O
differentiation	O
.	O

Patients	O
in	O
the	O
WMG	O
were	O
treated	O
with	O
donepezil	B-I
at	O
a	O
dose	O
of	O
5	O
mg	O
once	O
daily	O
.	O

The	O
therapeutic	O
course	O
lasted	O
48	O
weeks	O
.	O

The	B-O
scores	I-O
of	I-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
Fuld	B-O
Object	I-O
-	I-O
Memory	I-O
Evaluation	I-O
(	I-O
FOM	I-O
)	I-O
,	O
Block	B-O
Design	I-O
(	I-O
BD	I-O
)	I-O
and	O
Digit	B-O
Span	I-O
(	I-O
DS	I-O
)	I-O
were	O
used	O
to	O
evaluate	O
the	B-O
cognitive	I-O
function	I-O
;	O
resting	B-O
-	I-O
state	I-O
fMRI	I-O
was	O
used	O
for	O
observing	O
brain	B-O
function	I-O
.	O

The	B-O
questionnaires	I-O
and	O
fMRI	B-O
were	O
performed	O
before	O
and	O
after	O
treatments	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
psychosocial	O
intervention	O
in	O
patients	B-P
with	I-P
mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
the	O
multicentre	O
,	O
rater	O
blinded	O
,	O
randomised	O
Danish	O
Alzheimer	O
Intervention	O
Study	O
(	O
DAISY	O
)	O
.	O

METHODS	O
:	O
Multicentre	O
,	O
randomised	O
,	O
controlled	O
,	O
rater	O
blinded	O
trial	O
.	O

Primary	O
care	O
and	O
memory	O
clinics	O
in	O
five	O
Danish	O
districts	O
.	O

330	B-P
outpatients	I-P
with	I-P
mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
and	I-P
their	I-P
330	I-P
primary	I-P
care	I-P
givers	I-P
.	O

Participating	O
dyads	O
(	O
patient	O
and	O
primary	O
care	O
giver	O
)	O
were	O
randomised	O
to	O
control	B-C
support	I-C
during	O
follow	O
-	O
up	O
or	O
to	O
control	B-C
support	I-C
plus	O
DAISY	B-I
intervention	I-I
(	O
multifaceted	B-I
and	I-I
semi	I-I
-	I-I
tailored	I-I
counselling	I-I
,	O
education	B-I
,	O
and	O
support	B-I
)	O
.	O

Primary	O
outcomes	O
at	O
12	O
months	O
for	O
patients	O
were	O
change	O
from	O
baseline	O
in	O
mini	B-O
mental	I-O
state	I-O
examination	I-O
(	I-O
MMSE	I-O
)	I-O
score	I-O
,	O
Cornell	B-O
depression	I-O
scale	I-O
score	I-O
,	O
and	O
proxy	B-O
rated	I-O
European	I-O
quality	I-O
of	I-O
life	I-O
visual	I-O
analogue	I-O
scale	I-O
(	I-O
EQ	I-O
-	I-O
VAS	I-O
)	I-O
score	I-O
.	O

For	O
care	O
givers	O
,	O
outcomes	O
were	O
change	O
from	O
baseline	O
in	O
geriatric	B-O
depression	I-O
scale	I-O
(	I-O
GDS	I-O
30	I-O
items	I-O
)	I-O
score	I-O
and	O
EQ	B-O
-	I-O
VAS	I-O
score	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Psychosocial	B-I
care	I-I
assistants	I-I
caring	I-I
for	O
residents	B-P
with	I-P
dementia	I-P
according	I-P
to	I-P
section	I-P
87	I-P
b	I-P
SGB	I-P
XI	I-P
.	O

Emotional	O
and	O
cognitive	O
effects	O
]	O
.	O

METHODS	O
:	O
Using	O
a	O
longitudinal	O
control	O
group	O
design	O
the	O
effects	O
of	O
additional	B-I
low	I-I
threshold	I-I
psychosocial	I-I
assistance	I-I
were	O
recorded	O
and	O
analysed	O
for	O
ten	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
ASCOMALVA	O
trial	O
:	O
association	O
between	O
the	B-I
cholinesterase	I-I
inhibitor	I-I
donepezil	I-I
and	O
the	B-I
cholinergic	I-I
precursor	I-I
choline	I-I
alphoscerate	I-I
in	O
Alzheimer	O
'	O
s	O
disease	O
with	O
cerebrovascular	O
injury	O
:	O
interim	O
results	O
.	O

METHODS	O
:	O
ASCOMALVA	O
is	O
a	O
double	O
-	O
blind	O
multicentre	O
trial	O
that	O
has	O
completed	O
the	O
first	O
12	O
months	O
of	O
observation	O
of	O
91	B-P
patients	I-P
of	I-P
the	I-P
210	I-P
planned	I-P
.	O

Patients	O
were	O
aged	O
between	O
56	O
and	O
91	O
years	O
(	O
mean	O
75	O
	O
10	O
years	O
)	O
and	O
were	O
included	O
in	O
the	O
protocol	O
with	O
a	O
MMSE	O
score	O
between	O
15	O
and	O
24	O
.	O

Patients	B-P
with	I-P
AD	I-P
diagnosed	I-P
according	I-P
to	I-P
the	I-P
DSM	I-P
IV	I-P
criteria	I-P
suffer	I-P
from	I-P
ischemic	I-P
brain	I-P
damage	I-P
documented	I-P
by	I-P
neuroimaging	I-P
(	I-P
MRI	I-P
and	I-P
CT	I-P
scan	I-P
)	I-P
,	I-P
with	I-P
a	I-P
score?2	I-P
in	I-P
at	I-P
least	I-P
one	I-P
subfield	I-P
of	I-P
the	I-P
New	I-P
Rating	I-P
Scale	I-P
for	I-P
Age	I-P
-	I-P
Related	I-P
White	I-P
Matter	I-P
Changes	I-P
(	I-P
ARWMC	I-P
)	I-P
.	O

Patients	O
were	O
randomly	O
allotted	O
to	O
an	O
active	O
treatment	O
group	O
(	O
donepezil	B-I
+	O
choline	B-I
alphoscerate	I-I
)	O
or	O
to	O
a	O
reference	O
treatment	O
group	O
(	O
donepezil	B-C
+	O
placebo	B-C
)	O
and	O
were	O
examined	O
after	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Cognitive	O
outcomes	O
after	O
sertaline	B-I
treatment	I-I
in	O
patients	B-P
with	I-P
depression	I-P
of	I-P
Alzheimer	I-P
disease	I-P
.	O

METHODS	O
:	O
Placebo	O
-	O
controlled	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
.	O

Outpatient	O
memory	O
clinics	O
at	O
five	O
academic	O
medical	O
centers	O
in	O
the	O
United	O
States	O
.	O

A	B-P
total	I-P
of	I-P
131	I-P
patients	I-P
with	I-P
dAD	I-P
(	I-P
60	I-P
men	I-P
)	I-P
and	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
scores	I-P
of	I-P
10	I-P
-	I-P
26	I-P
.	O

Sertraline	B-I
(	O
n	O
=	O
67	O
)	O
,	O
target	O
dose	O
of	O
100	O
mg	O
daily	O
or	O
matching	B-C
placebo	I-C
(	O
n	O
=	O
64	O
)	O
.	O

Caregivers	O
received	O
standardized	O
psychosocial	O
intervention	O
throughout	O
the	O
trial	O
.	O

Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
,	O
cognitive	B-O
subscale	I-O
of	I-O
the	I-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
,	O
letter	B-O
fluency	I-O
,	O
backward	B-O
digit	I-O
span	I-O
,	O
Symbol	B-O
Digit	I-O
Modalities	I-O
Test	I-O
,	O
and	O
Finger	B-O
Tapping	I-O
Test	I-O
,	O
administered	O
at	O
baseline	O
,	O
and	O
8	O
,	O
16	O
,	O
and	O
24	O
weeks	O
following	O
baseline	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
the	B-I
apolipoprotein	I-I
E	I-I
?4	I-I
allele	I-I
on	O
functional	O
MRI	O
during	O
n	O
-	O
back	O
working	O
memory	O
tasks	O
in	O
healthy	B-P
middle	I-P
-	I-P
aged	I-P
adults	I-P
.	O

METHODS	O
:	O
From	O
110	B-P
participants	I-P
,	I-P
81	I-P
individuals	I-P
without	I-P
objective	I-P
or	I-P
subjective	I-P
cognitive	I-P
impairment	I-P
underwent	O
APOE	O
genotyping	O
.	O

Nine	B-P
APOE4	I-P
carriers	I-P
and	I-P
9	I-P
age	I-P
-	I-P
and	I-P
sex	I-P
-	I-P
matched	I-P
non	I-P
-	I-P
APOE4	I-P
controls	I-P
were	O
recruited	O
for	O
fMRI	O
examinations	O
during	O
WM	O
tasks	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
pharmacology	O
of	O
ponezumab	B-I
(	I-I
PF	I-I
-	I-I
04360365	I-I
)	I-I
after	O
a	O
single	O
10	O
-	O
minute	O
intravenous	O
infusion	O
in	O
subjects	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
disease	I-P
.	O

METHODS	O
:	O
Subjects	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
received	O
ponezumab	B-I
1	O
mg	O
/	O
kg	O
(	O
n	O
=	O
3	O
)	O
,	O
3	O
mg	O
/	O
kg	O
(	O
n	O
=	O
3	O
)	O
,	O
5	O
mg	O
/	O
kg	O
(	O
n	O
=	O
4	O
)	O
,	O
or	O
10	O
mg	O
/	O
kg	O
(	O
n	O
=	O
5	O
)	O
.	O

They	O
were	O
followed	O
up	O
as	O
outpatients	O
for	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Intravenous	B-I
immunoglobulin	I-I
for	O
treatment	O
of	O
mild	O
-	O
to	O
-	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
phase	O
2	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
dose	O
-	O
finding	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
multicentre	O
,	O
placebo	O
-	O
controlled	O
phase	O
2	O
trial	O
at	O
seven	O
sites	O
in	O
the	O
USA	O
and	O
five	O
in	O
Germany	O
.	O

Participants	B-P
with	I-P
probable	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
aged	I-P
50	I-P
-	I-P
85	I-P
years	I-P
were	O
randomly	O
assigned	O
(	O
by	O
a	O
computer	O
-	O
generated	O
randomisation	O
sequence	O
,	O
with	O
block	O
sizes	O
of	O
eight	O
)	O
to	O
infusions	O
every	O
4	O
weeks	O
(	O
02	B-I
,	O
05	B-I
,	O
or	O
08	B-I
g	I-I
intravenous	I-I
immunoglobulin	I-I
per	O
kg	O
bodyweight	O
,	O
or	O
placebo	B-C
)	O
or	O
infusions	O
every	O
2	O
weeks	O
(	O
01	B-I
,	O
025	B-I
,	O
or	O
04	B-I
g	I-I
/	I-I
kg	I-I
,	O
or	O
placebo	B-C
)	O
.	O

Patients	O
,	O
caregivers	O
,	O
investigators	O
assessing	O
outcomes	O
,	O
and	O
staff	O
at	O
imaging	O
facilities	O
and	O
the	O
clinical	O
research	O
organisation	O
were	O
masked	O
to	O
treatment	O
allocation	O
,	O
but	O
dispensing	O
pharmacists	O
,	O
the	O
statistician	O
,	O
and	O
the	O
person	O
responsible	O
for	O
final	O
PET	O
analyses	O
were	O
not	O
.	O

Treatment	O
was	O
masked	O
with	O
opaque	O
pouches	O
and	O
infusion	O
lines	O
.	O

The	O
primary	O
endpoint	O
was	O
median	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
of	O
plasma	B-O
amyloid	I-O
?	I-O
(	I-O
A?	I-O
)	I-O
(	I-O
1	I-O
-	I-O
40	I-O
)	I-O
between	O
the	O
last	O
infusion	O
and	O
the	O
final	O
visit	O
(	O
2	O
weeks	O
or	O
4	O
weeks	O
depending	O
on	O
infusion	O
interval	O
)	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
.	O

The	O
trial	O
is	O
registered	O
at	O
ClinicalTrials	O
.	O
gov	O
(	O
NCT00812565	O
)	O
and	O
controlled	O
-	O
trials	O
.	O
com	O
(	O
ISRCTN64846759	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
SolCos	B-I
model	I-I
-	I-I
based	I-I
individual	I-I
reminiscence	I-I
on	O
older	B-P
adults	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
dementia	I-P
due	I-P
to	I-P
Alzheimer	I-P
disease	I-P
:	O
a	O
pilot	O
study	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
82	B-P
older	I-P
adults	I-P
with	I-P
probable	I-P
AD	I-P
were	O
recruited	O
from	O
psychiatric	O
day	O
care	O
,	O
inpatient	O
,	O
and	O
long	O
term	O
care	O
facilities	O
.	O

Of	O
the	O
study	O
group	O
,	O
41	O
participants	O
were	O
randomly	O
selected	O
for	O
individual	B-I
reminiscence	I-I
sessions	I-I
during	O
4	O
weeks	O
performed	O
by	O
1	O
facilitator	O
.	O

A	O
control	O
group	O
of	O
41	O
older	O
adults	O
were	O
randomly	O
involved	O
and	O
had	O
no	B-C
planned	I-C
reminiscence	I-C
treatment	I-C
of	O
any	O
kind	O
in	O
the	O
study	O
period	O
.	O

All	O
study	O
participants	O
were	O
tested	O
pre	O
-	O
and	O
postintervention	O
period	O
with	O
validated	O
assessment	O
scales	O
to	O
evaluate	O
cognition	B-O
and	O
behavior	B-O
.	O

Analyses	O
were	O
based	O
on	O
delta	O
scores	O
,	O
the	O
differences	O
between	O
assessment	O
scales	O
pre	O
-	O
and	O
postintervention	O
scores	O
,	O
compared	O
between	O
the	O
intervention	O
and	O
the	O
control	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Phase	O
I	O
study	O
on	O
the	O
pharmacokinetics	O
and	O
tolerance	O
of	O
ZT	B-I
-	I-I
1	I-I
,	O
a	B-I
prodrug	I-I
of	I-I
huperzine	I-I
A	I-I
,	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
double	O
-	O
blinded	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
,	O
single	O
-	O
and	O
multiple	O
-	O
dose	O
study	O
.	O

For	O
the	O
single	O
-	O
dose	O
study	O
,	O
9	B-P
subjects	I-P
were	O
randomly	O
divided	O
into	O
3	O
groups	O
receiving	O
ZT	B-I
-	I-I
1	I-I
(	O
0	O
.	O
5	O
,	O
0	O
.	O
75	O
or	O
1	O
mg	O
,	O
po	O
)	O
according	O
to	O
a	O
Three	O
-	O
way	O
Latin	O
Square	O
Design	O
.	O

For	O
the	O
multiple	O
-	O
dose	O
study	O
,	O
9	B-P
subjects	I-P
receiving	O
ZT	B-I
-	I-I
1	I-I
(	O
0	O
.	O
75	O
mg	O
/	O
d	O
,	O
po	O
)	O
for	O
8	O
consecutive	O
days	O
.	O

In	O
the	O
tolerance	O
study	O
,	O
40	B-P
subjects	I-P
were	O
randomly	O
divided	O
into	O
5	O
groups	O
receiving	O
a	B-I
single	I-I
dose	I-I
of	I-I
ZT	I-I
-	I-I
1	I-I
(	O
0	O
.	O
5	O
,	O
0	O
.	O
75	O
,	O
1	O
,	O
1	O
.	O
25	O
or	O
1	O
.	O
5	O
mg	O
,	O
po	O
)	O
.	O

Plasma	B-O
and	O
urine	B-O
concentrations	I-O
of	I-O
ZT	I-O
-	I-O
1	I-O
and	O
Hup	B-O
A	I-O
were	O
determined	O
using	O
LC	B-O
-	I-O
MS	I-O
/	I-O
MS	I-O
.	O

Pharmacokinetic	B-O
parameters	I-O
,	O
including	O
Cmax	B-O
,	O
AUC0	B-O
-	I-O
72	I-O
h	I-O
and	O
AUC0	B-O
-	I-O
?	I-O
were	O
calculated	O
.	O

Tolerance	B-O
assessments	I-O
were	O
conducted	O
throughout	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
rivastigmine	B-I
in	O
comparison	O
to	O
ginkgo	B-C
for	O
treating	O
Alzheimer	O
'	O
s	O
dementia	O
.	O

METHODS	O
:	O
Total	B-P
56	I-P
patients	I-P
aged	I-P
50	I-P
-	I-P
75	I-P
years	I-P
,	I-P
suffering	I-P
from	I-P
dementia	I-P
,	O
were	O
allocated	O
into	O
one	O
of	O
the	O
two	O
treatments	O
:	O
group	O
1	O
)	O
Ginkgo	B-C
biloba	I-C
(	O
120	O
mg	O
daily	O
dose	O
)	O
;	O
group	O
2	O
)	O
rivastigmine	B-I
(	O
4	O
.	O
5	O
mg	O
daily	O
dose	O
)	O
in	O
a	O
24	O
-	O
week	O
randomized	O
double	O
blind	O
study	O
.	O

The	B-O
degree	I-O
of	I-O
severity	I-O
of	I-O
dementia	I-O
was	O
assessed	O
by	O
the	B-O
Seven	I-O
Minute	I-O
test	I-O
and	O
the	B-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
efficacy	O
of	O
methylphenidate	B-I
for	O
apathy	O
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Six	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
multicenter	O
trial	O
enrolling	O
Alzheimer	B-P
'	I-P
s	I-P
disease	I-P
participants	I-P
(	I-P
NINCDS	I-P
-	I-P
ADRDA	I-P
criteria	I-P
)	I-P
with	I-P
apathy	I-P
assigned	O
to	O
methylphenidate	B-I
20	O
mg	O
daily	O
or	O
placebo	B-C
,	O
conducted	O
from	O
June	O
2010	O
to	O
December	O
2011	O
.	O

Primary	O
outcomes	O
were	O
change	O
in	O
Apathy	B-O
Evaluation	I-O
Scale	I-O
(	I-O
AES	I-O
)	I-O
score	I-O
and	O
modified	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
ADCS	I-O
-	I-O
CGI	I-O
-	I-O
C	I-O
)	I-O
.	O

Secondary	O
outcomes	O
included	O
change	O
in	O
Neuropsychiatric	B-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
apathy	I-O
score	I-O
,	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
score	I-O
,	O
and	O
safety	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
non	I-I
-	I-I
focal	I-I
plasticity	I-I
protocol	I-I
on	O
apathy	O
in	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
sham	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Forty	B-P
patients	I-P
were	O
randomized	O
to	O
receive	O
either	O
active	B-I
or	O
sham	B-C
-	I-C
tDCS	I-C
over	O
the	O
left	O
dorsolateral	O
prefrontal	O
cortex	O
(	O
DLPFC	O
)	O
.	O

Patients	O
received	O
six	O
sessions	O
of	O
intervention	O
during	O
2	O
weeks	O
and	O
were	O
evaluated	O
at	O
baseline	O
,	O
at	O
week	O
1	O
and	O
2	O
,	O
and	O
after	O
1	O
week	O
without	O
intervention	O
.	O

Clinical	O
raters	O
,	O
patients	O
,	O
and	O
caregivers	O
were	O
blinded	O
.	O

The	O
primary	O
outcome	O
was	O
apathy	B-O
.	O

Global	B-O
cognition	I-O
and	O
neuropsychiatric	B-O
symptoms	I-O
were	O
examined	O
as	O
secondary	O
outcomes	O
.	O

